Ethical issues in the pharmaceutical industry: An analysis of US newspapers

International Journal of Pharmaceutical and Healthcare Marketing

Volumn 2, Issue 3, 2008, Pages 163-180

  Sillup, George P ^a   Porth, Stephen J ^a  

^a SAINT JOSEPH S UNIVERSITY   (United States)

Author keywords

Drug administration; Ethics; Health and safety; Mass media; Newspapers; Pharmaceuticals industry

Indexed keywords

EID: 79959799604     PISSN: 17506123     EISSN: None     Source Type: Journal    
DOI: 10.1108/17506120810903953     Document Type: Article

References (67)

1. Angell, M. (2004), The Truth about the Drug Companies: How They Deceive Us and What To Do about It, 1st ed., Random House, New York, NY.
2. Bale, H.E. (2005), “Industry, innovation and social values”, Science Engineering Ethics, Vol. 11 No. 1, pp. 31-40.
3. Barrett, J. and Jay, P. (2005), “Clinical research fraud: a victimless crime?”, Applied Clinical Trials, Vol. 12 No. 2, pp. 44-6.
4. Beauchamp, T.L., Jennings, B. and Kinney, E.D. (2002), “Pharmaceutical research involving the homeless”, Journal of Medical Philosophy, Vol. 27 No. 5, pp. 547-64.
5. Berenson, A. (2005), “Despite vow, drug makers still withhold data”, The New York Times, May 31, p. 1.
6. Blumenthal, D. (2004), “Doctors and drug companies”, New England Journal of Medicine, Vol. 351 No. 18, pp. 1885-90.
7. Brannon, M. (2005), “Drug ads let patients participate in care”, The USA Today, Editorial, June 15, p. 10A.
8. Brett, A.S., Burr, W. and Moloo, J. (2003), “Are gifts from pharmaceutical companies ethically problematic?: a survey of physicians”, Annals of Internal Medicine, Vol. 163 No. 18, pp. 2213-9.
9. Chandra, A. and Holt, G.A. (1999), “Pharmaceutical advertisements: how they deceive patients”, Journal of Business Ethics, Vol. 18 No. 4, pp. 359-66.
10. Consumer Report (2006), “Prescription for trouble”, CR Investigates, pp. 34-9.
11. Davidson, R. (2004), “Prescribing fixes to a broken system”, Applied Clinical Trials, Vol. 13 No. 8, p. 58.
12. Dimasi, J.A. and Paquette, C. (2004), “The economics of follow-on drug research and development: trends in entry rates and the timing of development”, Pharmacoeconomics, Vol. 22, Supplement 2, pp. 1-14.
13. Edmunds, M. (2004), “Confusing ethical guidelines dampen pharmaceutical support”, Nurse Practioner, Vol. 29 No. 8, p. 16.
14. Flaherty, M.P. and Gilbert, M.G. (2003), “Millions of Americans look outside US for drugs; desire for low prices often outweighs obeying laws”, The Washington Post, October 23, p. A01.
15. Fombrun, C. and Foss, C. (2004), “Business ethics: corporate responses to scandal”, Corporate Reputation Review, Vol. 7 No. 3, pp. 284-8.
16. Gewertz, N.M. and Amado, R. (2004), “Intellectual property and the pharmaceutical industry: a moral crossroads between health and property”, Journal of Business Ethics, Vol. 55 No. 3, pp. 295-308.
17. Goldberg, R.H. (2003), “False economy on drugs”, The Washington Post, Editorial, September 14, p. B07.
18. Goozner, M. (2004), The $800 Million Dollar Pill the Truth behind the Costs of New Drugs, University of California Press, Berkeley, CA.
19. Goozner, M. (2005), “Doctors who write guidelines often have ties to the drug industry”, British Medical Journal, Vol. 331, pp. 7523-82.
20. Hanekamp, G. (2005), “Business ethics of innovation”, Poesis and Praxis, Vol. 3 No. 4, pp. 310-4.
21. Heacock, M.V. (1990), “Ethical considerations and ramifications of the 1989 generic drug scandal”, Bridges: Interdisciplinary Journal of Theology, Philosophy, History, Science, Fall-Winter, pp. 113-25.
22. HeadlineSpot.com Lists (2007), “Top 100 daily US newspapers by circulation”, available at: www.infoplease.com/ipea/A0004420.html (accessed March 21 2007).
23. Healy, D. (2000), “Good science or good business?”, Hastings Center Report, Vol. 30 No. 2, pp. 19-22.
24. Healy, D. (2003), “In the grip of the python: conflicts at the university-industry interface”, Science and Engineering Ethics, Vol. 9 No. 1, pp. 59-71.
25. Heller, S. (2004), “Untitled”, Diabetes Medicine, Vol. 12 No. 9, Editorial, p. 961.
26. Herxheimer, A. (1996), “Side effects: freedom of information and the communication of doubt”, International Journal of Risk & Safety in Medicine, Vol. 9, pp. 201-10.
27. Herxheimer, A. (1999), “Secret out-of-court settlements in drug-injury cases”, The Lancet, Vol. 353 No. 9152, pp. 517-9.
28. Homer, A.F. (2004), “Information is available”, The USA Today, Editorial, August 10, p. 10A.
29. Johnson & Johnson (2005), Annual Report, back cover, Johnson & Johnson, New Brunswick, NJ.
30. Kaiser, J. (2005), “Final NIH rules ease stock limits”, Science, Vol. 309 No. 5740, p. 1469.
31. Kassirer, J.P. (2005), On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health, Oxford University Press, New York, NY.
32. Katz, D., Caplan, A.L. and Merz, J.F. (2003), “All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-offering”, American Journal of Bioethics, Vol. 3 No. 3, pp. 39-46.
33. Kerridge, I., Maguire, J., Newby, D., Mcneill, P.M., Henry, D., Hill, S., Day, R., Macdonald, G., Stokes, B. and Henderson, K. (2005), “Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations”, International Medical Journal, Vol. 35 No. 4, pp. 206-10.
34. Kmietowicz, Z. (2004), “Second drug firm found guilty of ‘switching’ patients to new drugs”, British Medical Journal, Vol. 329 No. 741, p. 875.
35. Koren, G. (2003), “Healthy children as subjects in pharmaceutical research”, Theoretical Medicine and Bioethics: Philosophy of Medical Research Practice, Vol. 24 No. 2, pp. 149-59.
36. (The) Lancet (2004a), “How, when and where should trial data be presented?”, The Lancet, Vol. 364 No. 9447, Editorial, November 11, p. 1730.
37. (The) Lancet (2004b), “Vioxx: an unequal partnership between safety and efficacy”, The Lancet, Vol. 364 No. 9442, pp. 1287-8, Editorial, October 9.
38. Lenzer, J. (2005), “Doctors refuse space to group fighting drug company influence”, British Medical Journal, Vol. 331, pp. 7518-653.
39. Maitland, I. (2002), “Priceless goods: how should life-saving drugs be priced?”, Business Ethics Quarterly, Vol. 12 No. 4, pp. 451-80.
40. Marris, E. (2005), “NIH ethics rules come off probation”, Nature, Vol. 437 No. 7055, p. 9.
41. Marsa, L. (1997), Prescription for Profits: How the Pharmaceutical Industry Bankrolled the Unholy Marriage between Science and Business, Scribner Publishing, New York, NY.
42. Masek, L. (2000), “The doctrine of the double effect: deadly drugs and business ethics”, Business Ethics Quarterly, Vol. 10 No. 2, pp. 483-95.
43. Masters, B.A. (2004), “Drug firm shares in slump”, The Washington Post, Editorial, November 12, p. E01.
44. Moynihan, R. and Cassels, A. (2005), Selling Sickness: How the World's Biggest Pharmaceutical Companies are Turning us all into Patients, Avalon Publishing Co., Bound Brook, NJ.
45. Naik, G. (2004), “Iron lady: Nigerian regulator dodges violence to fight fake drugs”, The Wall Street Journal, May 28, p. A1.
46. Offit, P.A. (2005), The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis, Yale University Press, New Haven, CT.
47. Olivieri, N.F. (2003), “Patients' health or company profits? The commersialisation of academic research”, Science and Engineering Ethics, Vol. 9 No. 1, pp. 29-41.
48. Ornellana, C. (2002), “German doctors' links with drug firm investigated”, The Lancet, Vol. 359 No. 9311, p. 1039.
49. Pepin, J.F. (1996), “Pharmaceutical sales representatives and physicians: ethical considerations of a relationship”, Journal of Medical Philosophy, Vol. 21 No. 1, pp. 83-99.
50. Pepin, J.F. (1997), “An englehardtian analysis of interactions between pharmaceutical sales representatives and physicians”, Journal of Medical Philosophy, Vol. 22 No. 6, pp. 623-41.
51. Pinkus, R.L. (2002), “From Lydia Pinkham to Bob Doyle: what the changing face of direct-to-consumer advertising reveals about the professionalism of medicine”, Kennedy Institute of Ethics, Vol. 12 No. 2, pp. 141-58.
52. Rau, J. (2004), “Ballot items aimed at Gov”, The Los Angeles Times, December 25, p. A1.
53. Schieppati, A., Perico, N. and Remuzzi, G. (2002), “Conflict of interest as seen from a researcher's perspective”, Science and Engineering Ethics, Vol. 8 No. 3, pp. 337-42.
54. Shuchman, M. (2002), “The Olivieri dispute; no end in sight”, Canadian Medical Association Journal, Vol. 166 No. 4, p. 487.
55. Shuchman, M. (2005), The Drug Trial: Nancy Olivieri and the Science Scandal That Rocked the Hospital for Sick Children, Random House of Canada, Ltd, Toronto, ON.
56. Sierles, F.S., Brodkey, A.C., Cleary, L.M., McCurdy, F.A., Mintz, M., Frank, J., Lynn, D.J., Chao, J., Morgenstern, B.Z., Shore, W. and Woodard, J.L. (2005), “Medical students' exposure to and attitudes about drug company interactions: a national survey”, Journal of the American Medical Association, Vol. 294 No. 9, pp. 1034-42.
57. Spilker, B. (1984), “Myths and misconceptions about drug industry ethics”, International Journal of Applied Philosophy, Vol. 2, pp. 1-12.
58. Studdert, D.M., Mello, M.M. and Brennan, T.A. (2004), “Financial conflicts of interest in physicians' relationships with the pharmaceutical industry – self-regulation in the shadow of federal prosecution”, New England Journal of Medicine, Vol. 35 No. 18, pp. 1891-900.
59. Tishler, C.L. and Gordon, L.B. (1999), “Ethical parameters of challenge studies inducing psychosis with ketamine”, Ethics Behavior, Vol. 9 No. 3, pp. 211-7.
60. Vallance, P. (2005), “Developing an open relationship with the drug industry”, The Lancet, Vol. 336 No. 9491, pp. 1062-4.
61. Veatch, R.M. (1985), “Case study: the HMO physician's duty to cut costs – a commentary”, Hastings Center Report, Vol. 15, pp. 13-14.
62. Vedantam, S. (2004), “Drug makers prefer silence on test data; firms violate US law by not registering trials”, The Washington Post, July 6, p. A01.
63. Wagena, E.J. and Knipschild, P. (2005), “Do drug firms hoodwink medical journals? Or is something wrong with the contribution and integrity of declared authors?”, Journal of Medical Ethics, Vol. 31 No. 6, p. 307.
64. Walker, H.D. (1971), Market Power and Price Levels in the Ethical Drug Industry, Indiana University Press, Bloomington, IN.
65. (The) Washington Post Editorial Board (2004a), “Dealing drugs”, The Washington Post, Editorial, March 15, p. A24.
66. (The) Washington Post Editorial Board (2004b), “Missing drug data”, The Washington Post, Editorial, June 30, p. A20.
67. Welch, W.M. (2005), “Drug prices outstrip inflation; study: brand names' cost up 7.1% last year”, The USA Today, April 12, p. A1.